Japan And Cambridge

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 27, 2011 - Takeda Pharmaceutical Company Limited (TSE:4502) together with its wholly-owned subsidiary Millennium: The Takeda Oncology Company, today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for ADCETRIS™ (brentuximab vedotin) for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).